Navigation Links
O2h to Provide Chemistry Support to Chromocell
Date:6/23/2011

CAMBRIDGE, England, AHMEDABAD, India and NORTH BRUNSWICK, New Jersey, June 23, 2011 /PRNewswire/ --


 

Oxygen Healthcare Ltd. (O2h), a Piramal Group Company and Chromocell Corporation, an emerging life sciences company active in both flavors and therapeutics discovery, today signed an agreement under which O2h will provide supplemental chemistry support to further accelerate the drug discovery initiatives at Chromocell.  

"I have known O2h for a number of years and am impressed by its delivery focus," said David Palling, Senior Vice President, Therapeutics, Chromocell. "With the in-house chemistry resources and the faster-than-expected progress made in our therapeutic programs, complementary support from O2h will help us maximize resources and reach our end-points quicker.  I look forward to this opportunity of working with them to advance our drug discovery pipeline."

O2h will provide Chromocell during 2011 with focused libraries of compounds at mg-g scale for various projects.

Sunil Shah, CEO, O2h said "O2h has optimized its operations for discovery speed and delivery to help accelerate drug discovery efforts of companies in the United States, Europe and Japan. It is our privilege to work with the experienced team led by Dr. Palling at Chromocell,"  

About Chromocell Corporation

Chromocell, founded in 2002 and headquartered in North Brunswick, N.J., is an emerging life sciences company which improves consumer products and patient lives through breakthrough science and technologies.  It is focused on the discovery and development of both flavors and therapeutics through its pioneering Chromovert ® technology, a process that enables the company to use naturally occurring systems that mimic human biology as part of its discovery platform.  Chromocell works with worldwide consumer goods companies to develop flavor ingredients and sweetness enhancers.  Its therapeutics program is concentrated on pain relief, respiratory diseases, and other disorders where Chromovert technology offers the advantage of addressing complex and intractable targets. For more information, go to http://www.chromocell.com.

About O2h, a Piramal Group Company

O2h is the discovery services arm of Piramal Pharma Solutions Ltd, a top 10 global CRAMS group, offering a unique full-service partnership at every stage of the pharma life-cycle. Piramal Pharma Solutions employs 2,500 people across 9 specialist sites in North America, UK and India. The Piramal group has a 140 year history and is publicly listed company (BSE: PIRAMALHE).

O2h's 200 employees work within its project management office in Cambridge, UK and its operations in Ahmedabad India. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan.O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based medicinal, synthetic chemistry, and process chemistry as well as in vitro biology services. Further information on O2h can be found at http://www.o2h.com.

Contact:

Ekta Ahuja PhD
O2h
23, Cambridge Science Park    
CB4 0EY
info@o2h.com    

Barbara Shear
Chromocell Corporation
685 U.S. Highway One
North Brunswick, NJ 08902

 


'/>"/>
SOURCE O2h
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Visual Healthcare Provides Fourth Quarter Revenue Guidance
2. Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date
3. Cell Therapeutics Completes Type A Meeting With FDAs Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval
4. Tengion Provides Update on Neo-Urinary Conduit Clinical Trial
5. Friends of Disabled Adults and Children Partners With Invacare to Provide Aid in Wake of Joplin Tornado
6. Vertex Plans to Provide Access to Potential CF Therapy VX-770 for Patients with Critical Medical Need
7. XTRAC Laser Provides New Hope for Children with Psoriasis
8. Edison Pharmaceuticals to Provide Expanded Access to EPI-743 for Mitochondrial Disease
9. Oregon Homecare Providers Support Congressional Bill to Repeal Misguided Medicare Bidding Program
10. CVS Caremark and Area Colleagues Provide $40,000 of Support to Tornado Relief Efforts in Joplin, MO
11. Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
(Date:4/29/2016)... ... 2016 , ... CURE Media Group , the nation’s ... today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci Cancer Center in ... Oncology Nursing , which honors nurses who have dedicated their careers to helping ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, Inc. ... line of probiotics, Petbiotics ™, as they fondly call them. As animal ... groups networking for their non-profit organizations. Animal rescues across the nation face huge ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in ... efficacy of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... 2014. Each year, reproductive endocrinologists are required to report in vitro fertilization ... of professionals dedicated to the practice of assisted reproductive technologies in the United ...
Breaking Medicine News(10 mins):